Perspective Therapeutics Inc (CATX)

$3.01 +0.10 (3.44%)
Market Cap 331.87M
Revenue (ttm) 880,000.00
Net Income (ttm) -103.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11,718.18%
Debt to Equity Ratio 0.00
Volume 871,900
Avg Vol 1,796,444
Day's Range N/A - N/A
Shares Out 114.05M
Stochastic %K 91%
Beta 1.74
Analysts Strong Sell
Price Target $12.79

Company Profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a b...

Industry: Medical Devices
Sector: Healthcare
Phone: 206 676 0900
Address:
2401 Elliott Avenue, Suite 320, Seattle, United States
noble23
noble23 Aug. 4 at 3:16 PM
$CATX patients and accumulation is gonna win big here!
1 · Reply
Miura1957
Miura1957 Aug. 4 at 3:13 PM
$CATX every day…
0 · Reply
jto2
jto2 Aug. 4 at 11:56 AM
$CATX Commodore reported 11,939,753 shares 9.9% Lantheus reported 11,677,339 shares. roughly, 10%
0 · Reply
Sayknee
Sayknee Aug. 3 at 9:31 PM
$CATX Roughly, 20% of our little CATX is now owned by, https://www.linkedin.com/posts/news-radiopharmaceuticals-leadingradiopharma-ugcPost-7490007167064809472-HsBY/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAi0tAsB9OUbyQdeIOoco31_MUyDCltdm0Q
1 · Reply
rughead64
rughead64 Aug. 3 at 7:24 PM
$CATX volume picking up a bit as is SP
0 · Reply
markbass2341
markbass2341 Aug. 3 at 6:28 PM
$CATX does that mean it’s a POS
0 · Reply
rughead64
rughead64 Aug. 3 at 5:48 PM
$CATX pathetic volume today
0 · Reply
Alacrity2
Alacrity2 Aug. 3 at 2:44 PM
$CATX Curium Agrees To Buy Lantheus In An $8 Billion Radiopharma Deal - Finimize https://finimize.com/content/curium-agrees-to-buy-lantheus-in-an-8-billion-radiopharma-deal
0 · Reply
Miura1957
Miura1957 Aug. 3 at 2:27 PM
$CATX why won’t they let it break 3🤔
1 · Reply
morty104
morty104 Aug. 3 at 11:57 AM
$CATX I’m calling a red open
0 · Reply
Latest News on CATX
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

Jul 31, 2026, 6:30 AM EDT - 4 days ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

Perspective Therapeutics: EC grants OMP designation to (212Pb)VMT-alpha-NET

2026-07-28T10:47:15.000Z - 7 days ago

Perspective Therapeutics: EC grants OMP designation to (212Pb)VMT-alpha-NET

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

Jul 28, 2026, 6:30 AM EDT - 7 days ago

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

Jul 17, 2026, 12:22 PM EDT - 17 days ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

Perspective Therapeutics management to meet virtually with BTIG

2026-07-10T17:55:37.000Z - 24 days ago

Perspective Therapeutics management to meet virtually with BTIG

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.

Jul 8, 2026, 6:30 AM EDT - 27 days ago

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.

Perspective Therapeutics management to meet virtually with BTIG

2026-06-26T19:25:28.000Z - 5 weeks ago

Perspective Therapeutics management to meet virtually with BTIG

Perspective announces first patient dosed with (212Pb)VMT-alpha-NET

2026-06-03T11:10:47.000Z - 2 months ago

Perspective announces first patient dosed with (212Pb)VMT-alpha-NET

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

Jun 3, 2026, 6:30 AM EDT - 2 months ago

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

May 21, 2026, 5:51 PM EDT - 2 months ago

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Perspective Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 2:05 PM EDT - 2 months ago

Perspective Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Perspective Therapeutics doses first patients in two Phase 1/2a studies

2026-05-18T10:35:48.000Z - 2 months ago

Perspective Therapeutics doses first patients in two Phase 1/2a studies

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

May 18, 2026, 6:30 AM EDT - 2 months ago

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

Perspective Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 5:20 PM EDT - 2 months ago

Perspective Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

Perspective Therapeutics price target lowered to $6 from $7 at BofA

2026-05-12T16:04:03.000Z - 2 months ago

Perspective Therapeutics price target lowered to $6 from $7 at BofA

Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)

2026-05-11T23:16:42.000Z - 3 months ago

Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

May 11, 2026, 4:07 PM EDT - 3 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

Perspective Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Perspective Therapeutics Earnings release: Q1 2026

Perspective Therapeutics Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Perspective Therapeutics Quarterly report: Q1 2026

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Apr 24, 2026, 6:30 AM EDT - 3 months ago

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

2026-04-20T10:10:51.000Z - 3 months ago

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Apr 20, 2026, 6:00 AM EDT - 3 months ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Perspective Therapeutics Proxy statement: Proxy filing

Perspective Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Perspective Therapeutics Proxy statement: Proxy filing

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Apr 2, 2026, 7:00 AM EDT - 4 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright

2026-03-23T10:10:08.000Z - 4 months ago

Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright

Perspective Therapeutics price target raised to $8 from $7 at UBS

2026-03-19T12:28:39.000Z - 4 months ago

Perspective Therapeutics price target raised to $8 from $7 at UBS

Perspective Therapeutics price target raised to $13 from $11 at B. Riley

2026-03-18T12:51:16.000Z - 4 months ago

Perspective Therapeutics price target raised to $13 from $11 at B. Riley

Perspective Therapeutics price target raised to $8 from $7 at UBS

2026-03-18T12:07:41.000Z - 4 months ago

Perspective Therapeutics price target raised to $8 from $7 at UBS

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Mar 17, 2026, 4:45 PM EDT - 4 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Mar 16, 2026, 4:07 PM EDT - 5 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics Annual report: Q4 2025

Mar 16, 2026, 4:00 PM EDT - 5 months ago

Perspective Therapeutics Annual report: Q4 2025

Perspective Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 4:00 PM EDT - 5 months ago

Perspective Therapeutics Earnings release: Q4 2025

Perspective Therapeutics initiated with an Overweight at Piper Sandler

2026-02-19T10:15:14.000Z - 5 months ago

Perspective Therapeutics initiated with an Overweight at Piper Sandler

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Feb 17, 2026, 7:00 AM EST - 6 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering

2026-02-02T13:46:01.000Z - 6 months ago

Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Feb 2, 2026, 8:35 AM EST - 6 months ago

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright

2026-01-30T11:10:55.000Z - 6 months ago

Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright

Perspective Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 5:15 PM EST - 7 months ago

Perspective Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics provides business updates, strategic priorities

2026-01-12T12:40:27.000Z - 7 months ago

Perspective Therapeutics provides business updates, strategic priorities

Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET

2026-01-09T12:10:58.000Z - 7 months ago

Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Jan 9, 2026, 7:00 AM EST - 7 months ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:00 AM EST - 8 months ago

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 1:00 PM EST - 8 months ago

Perspective Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Perspective Therapeutics to Participate in Upcoming December Conferences

Nov 20, 2025, 7:00 AM EST - 9 months ago

Perspective Therapeutics to Participate in Upcoming December Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Nov 10, 2025, 4:05 PM EST - 9 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Perspective Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 9 months ago

Perspective Therapeutics Quarterly report: Q3 2025

Perspective Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 4:00 PM EST - 9 months ago

Perspective Therapeutics Earnings release: Q3 2025

Perspective Therapeutics to Participate in Upcoming November Conferences

Oct 31, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Participate in Upcoming November Conferences

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 24, 2025, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Perspective Therapeutics Transcript: Study Update

Oct 20, 2025, 8:30 AM EDT - 10 months ago

Perspective Therapeutics Transcript: Study Update

Perspective Therapeutics Press release: Study Update

Oct 20, 2025, 8:30 AM EDT - 10 months ago

Perspective Therapeutics Press release: Study Update

Perspective Therapeutics Slides: Study Update

Oct 20, 2025, 8:30 AM EDT - 10 months ago

Perspective Therapeutics Slides: Study Update

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Oct 20, 2025, 4:00 AM EDT - 10 months ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Sep 3, 2025, 7:00 AM EDT - 11 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 26, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Perspective Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 9:30 AM EDT - 1 year ago

Perspective Therapeutics Quarterly report: Q2 2025

Perspective Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 9:30 AM EDT - 1 year ago

Perspective Therapeutics Earnings release: Q2 2025

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 13, 2025, 6:45 AM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 24, 2025, 12:45 PM EDT - 1 year ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Jun 21, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 30, 2025, 5:21 PM EDT - 1 year ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 12, 2025, 4:36 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Quarterly report: Q1 2025

Perspective Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Earnings release: Q1 2025

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

May 1, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 12:25 PM EDT - 1 year ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Perspective Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Proxy statement: Proxy Filing

Perspective Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Proxy statement: Proxy Filing

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Apr 11, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 26, 2025, 4:10 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Perspective Therapeutics Annual report: Q4 2024

Mar 26, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Annual report: Q4 2024

Perspective Therapeutics Earnings release: Q4 2024

Mar 26, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Earnings release: Q4 2024

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 3:30 PM EDT - 1 year ago

Perspective Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Perspective Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:10 AM EST - 1 year ago

Perspective Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 21, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Perspective Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 2:00 PM EST - 1 year ago

Perspective Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Feb 5, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Perspective Therapeutics Transcript: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Transcript: Status Update

Perspective Therapeutics Press release: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Press release: Status Update

Perspective Therapeutics Slides: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Slides: Status Update

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 24, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Perspective Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Jan 6, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Perspective Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 5, 2024, 10:50 AM EST - 1 year ago

Perspective Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Perspective Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 10:00 AM EST - 1 year ago

Perspective Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 27, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 9:10 AM EST - 1 year ago

Perspective Therapeutics Transcript: Stifel 2024 Healthcare Conference

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics Transcript: UBS Global Healthcare Conference

Nov 13, 2024, 5:45 PM EST - 1 year ago

Perspective Therapeutics Transcript: UBS Global Healthcare Conference

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Perspective Therapeutics Quarterly report: Q3 2024

Perspective Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Perspective Therapeutics Earnings release: Q3 2024

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

noble23
noble23 Aug. 4 at 3:16 PM
$CATX patients and accumulation is gonna win big here!
1 · Reply
Miura1957
Miura1957 Aug. 4 at 3:13 PM
$CATX every day…
0 · Reply
jto2
jto2 Aug. 4 at 11:56 AM
$CATX Commodore reported 11,939,753 shares 9.9% Lantheus reported 11,677,339 shares. roughly, 10%
0 · Reply
Sayknee
Sayknee Aug. 3 at 9:31 PM
$CATX Roughly, 20% of our little CATX is now owned by, https://www.linkedin.com/posts/news-radiopharmaceuticals-leadingradiopharma-ugcPost-7490007167064809472-HsBY/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAi0tAsB9OUbyQdeIOoco31_MUyDCltdm0Q
1 · Reply
rughead64
rughead64 Aug. 3 at 7:24 PM
$CATX volume picking up a bit as is SP
0 · Reply
markbass2341
markbass2341 Aug. 3 at 6:28 PM
$CATX does that mean it’s a POS
0 · Reply
rughead64
rughead64 Aug. 3 at 5:48 PM
$CATX pathetic volume today
0 · Reply
Alacrity2
Alacrity2 Aug. 3 at 2:44 PM
$CATX Curium Agrees To Buy Lantheus In An $8 Billion Radiopharma Deal - Finimize https://finimize.com/content/curium-agrees-to-buy-lantheus-in-an-8-billion-radiopharma-deal
0 · Reply
Miura1957
Miura1957 Aug. 3 at 2:27 PM
$CATX why won’t they let it break 3🤔
1 · Reply
morty104
morty104 Aug. 3 at 11:57 AM
$CATX I’m calling a red open
0 · Reply
noble23
noble23 Aug. 3 at 10:45 AM
$CATX let’s see some positivity today!
0 · Reply
CM62
CM62 Aug. 3 at 10:37 AM
$CATX I'm starting to eat humble pie, but it tastes great..SP going up..👏👏
0 · Reply
mittj
mittj Aug. 3 at 10:31 AM
$CATX
0 · Reply
CM62
CM62 Aug. 3 at 1:26 AM
$CATX It looks like the pre- market is ⬆️, but CATX ⬇️..??
0 · Reply
Alacrity2
Alacrity2 Aug. 3 at 12:00 AM
$CATX I am going to do a recap of just July’s news… the year is almost over most of us have been waiting for this! So the news for July 1, 2026 https://finance.yahoo.com/healthcare/articles/perspective-therapeutics-catx-reports-encouraging-220823316.html
3 · Reply
Alacrity2
Alacrity2 Aug. 1 at 5:21 AM
$CATX https://www.linkedin.com/posts/thijs-spoor-biotech_melanoma-targetedoncology-radiopharmaceuticals-share-7488998105606967296-2KVU/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAACVaBNsBrvfIvbW16ta28vS1MkGGk6XkjWE&utm_campaign=share_via
0 · Reply
CM62
CM62 Jul. 31 at 9:01 PM
$CATX Why is this stock down most days? Market up, it appears only good news. This is year's and years. I've been in it since Isoray. If the brachetheraphy and radio..is a standard of cure, why is this SP always go8ng ⬇️⬇️? Are upper level management big salaries going down,
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jul. 31 at 6:33 PM
$CATX
0 · Reply
ltcman
ltcman Jul. 31 at 2:41 PM
$CATX SSDD!
0 · Reply
morty104
morty104 Jul. 30 at 11:50 PM
$CATX $2.999998. Nothing fishy here
1 · Reply
markbass2341
markbass2341 Jul. 30 at 11:43 PM
$CATX come on 6 dollars
1 · Reply
rughead64
rughead64 Jul. 30 at 7:51 PM
$CATX lets close at HOD on volume
0 · Reply